keyword
MENU ▼
Read by QxMD icon Read
search

Elderly, chemotherapy, lung cancer

keyword
https://www.readbyqxmd.com/read/28527959/systemic-treatment-patterns-with-advanced-or-recurrent-non-small-cell-lung-cancer-in-japan-a-retrospective-hospital-administrative-database-study
#1
Feng Wang, Sari Mishina, Shinji Takai, T Kim Le, Kenya Ochi, Kotaro Funato, Shozo Matsuoka, Yuichiro Ohe
PURPOSE: Data on the treatment of non-small cell lung cancer (NSCLC) in real-world clinical practice in Japan are limited. This large-scale, retrospective cohort study examined data on patients' characteristics and systemic therapies for advanced or recurrent NSCLC in routine practice in Japan. METHODS: This study used an electronic health records-based database of health claims and Diagnosis Procedure Combination data from 215 consenting hospitals in Japan. Records from April 2008 to September 2015 were analyzed...
May 18, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28493811/pooled-analysis-of-individual-patient-data-on-concurrent-chemoradiotherapy-for-stage-iii-non-small-cell-lung-cancer-in-elderly-patients-compared-with-younger-patients-who-participated-in-us-national-cancer-institute-cooperative-group-studies
#2
Thomas E Stinchcombe, Ying Zhang, Everett E Vokes, Joan H Schiller, Jeffrey D Bradley, Karen Kelly, Walter J Curran, Steven E Schild, Benjamin Movsas, Gerald Clamon, Ramaswamy Govindan, George R Blumenschein, Mark A Socinski, Neal E Ready, Wallace L Akerley, Harvey J Cohen, Herbert H Pang, Xiaofei Wang
Purpose Concurrent chemoradiotherapy is standard treatment for patients with stage III non-small-cell lung cancer. Elderly patients may experience increased rates of adverse events (AEs) or less benefit from concurrent chemoradiotherapy. Patients and Methods Individual patient data were collected from 16 phase II or III trials conducted by US National Cancer Institute-supported cooperative groups of concurrent chemoradiotherapy alone or with consolidation or induction chemotherapy for stage III non-small-cell lung cancer from 1990 to 2012...
May 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28456908/use-of-prophylactic-growth-factors-and-antimicrobials-in-elderly-patients-with-cancer-a-review-of-the-medicare-database
#3
Romina Sosa, Shuling Li, Julia T Molony, Jiannong Liu, Scott Stryker, Allan J Collins
PURPOSE: Growth factors and antimicrobials can reduce complications of chemotherapy-induced myelosuppression. Their prophylactic use in elderly patients is important given the associated comorbidity in this age group. There is a developing trend by payers to include supportive care agents in chemotherapy care bundles, which could affect clinical practice. We examined whether the febrile neutropenia (FN) risk categories can be used to describe utilization in the Centers for Medicare & Medicaid fee-for-service system in older adults...
April 29, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28451422/erlotinib-as-second-or-third-line-treatment-in-elderly-patients-with-advanced-non-small-cell-lung-cancer-keio-lung-oncology-group-study-001-klog001
#4
Masayoshi Miyawaki, Katsuhiko Naoki, Satoshi Yoda, Sohei Nakayama, Ryosuke Satomi, Takashi Sato, Shinnosuke Ikemura, Keiko Ohgino, Kota Ishioka, Daisuke Arai, Ho Namkoong, Kengo Otsuka, Masaki Miyazaki, Tetsuo Tani, Aoi Kuroda, Makoto Nishino, Hiroyuki Yasuda, Ichiro Kawada, Hidefumi Koh, Morio Nakamura, Takeshi Terashima, Fumio Sakamaki, Koichi Sayama, Tomoko Betsuyaku, Kenzo Soejima
The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second- or third-line treatment for elderly Japanese patients with non-small-cell lung cancer (NSCLC). The patients eligible for this phase II trial were aged ≥70 years, had stage III/IV or recurrent NSCLC, and had previously received 1 or 2 chemotherapy regimens that did not include EGFR-TKIs. The patients received erlotinib at a dose of 150 mg/day. The primary endpoint was overall response rate (ORR), and the secondary endpoints were progression-free survival (PFS), overall survival (OS) and toxicity...
March 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28416124/assessment-of-the-external-validity-of-the-national-comprehensive-cancer-network-and-european-society-for-medical-oncology-guidelines-for-non-small-cell-lung-cancer-in-a-population-of-patients-aged-80-years-and-older
#5
REVIEW
Nicolò Matteo Luca Battisti, Marina Sehovic, Martine Extermann
Non-small-cell lung cancer (NSCLC) is a disease of the elderly, who are under-represented in clinical trials. This challenges the external validity of the evidence base for its management and of current guidelines, that we evaluated in a population of older patients. We retrieved randomized clinical trials (RCTs) supporting the guidelines and identified 18 relevant topics. We matched a cohort of NSCLC patients aged older than 80 years from the Moffitt Cancer Center database with the studies' eligibility criteria to check their qualification for at least 2 studies...
March 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28389722/undertreatment-trend-in-elderly-lung-cancer-patients-in-brazil
#6
Guilherme Jorge Costa, Maria Júlia Gonçalves de Mello, Carlos Gil Ferreira, Luiz Claudio Santos Thuler
PURPOSE: Elderly patients with lung cancer tend to be undertreated in comparison to younger patients. The objective of this study is to compare treatment modalities offered to lung cancer patients from 70 years of age or more with patients under 70. METHODS: For this study, an analytical cross-sectional epidemiological study conducted with data from the Brazilian hospital-based cancer registries between the years 2000 and 2011. In addition, odds ratios (OR) were calculated, with a 95% confidence intervals (95% CI), in conjunction with the construction of a logistic regression model...
April 7, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28366580/influence-of-age-on-guideline-concordant-cancer-care-for-elderly-patients-in-the-united-states
#7
Penny Fang, Weiguo He, Daniel R Gomez, Karen E Hoffman, Benjamin D Smith, Sharon H Giordano, Reshma Jagsi, Grace L Smith
PURPOSE: To examine the frequency of guideline-concordant cancer care in elderly patients, including "older" elderly (age ≥80 years). METHODS AND MATERIALS: Using the Surveillance, Epidemiology and End Results-Medicare dataset in patients aged ≥66 years diagnosed with nonmetastatic breast cancer (n=55,094), non-small cell lung (NSCLC) (n=36,203), or prostate cancer (n=86,544) from 2006 to 2011, chemotherapy, surgery, and radiation (RT) treatments were identified using claims...
February 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28366575/timed-get-up-and-go-test-and-geriatric-8-scores-and-the-association-with-chemo-radiation-therapy-noncompliance-and-acute-toxicity-in%C3%A2-elderly-cancer-patients
#8
Judith G Middelburg, Mirjam E Mast, Maaike de Kroon, Jan J Jobsen, Tom Rozema, Huub Maas, Elizabet A Baartman, Debby Geijsen, Annija H van der Leest, Desirée J van den Bongard, Judith van Loon, Tom Budiharto, Jan Willem Coebergh, Mieke J Aarts, Henk Struikmans
PURPOSE: To investigate whether the Geriatric 8 (G8) and the Timed Get Up and Go Test (TGUGT) and clinical and demographic patient characteristics were associated with acute toxicity of radiation therapy and noncompliance in elderly cancer patients being irradiated with curative intent. METHODS AND MATERIALS: Patients were eligible if aged ≥65 years and diagnosed with breast, non-small cell lung, prostate, head and neck, rectal, or esophageal cancer, and were referred for curative radiation therapy...
January 29, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28341958/randomized-phase-ii-study-comparing-weekly-docetaxel-cisplatin-vs-gemcitabine-cisplatin-in-elderly-or-poor-performance-status-patients-with-advanced-non-small-cell-lung-cancer
#9
JoungSoon Jang, Hoon-Kyo Kim, Byoung Chul Cho, Kyung Hee Lee, Hwan-Jung Yun, In Sook Woo, Hong Suk Song, Hun-Mo Ryoo, Chi-Hong Kim, Der-Sheng Sun, Jong Wook Shin
BACKGROUND: Docetaxel/cisplatin (DP) and gemcitabine/cisplatin (GP) are standard treatment regimens for advanced non-small cell lung cancer (NSCLC). In spite of potent efficacy, the conventional 1-day DP is regarded as having more toxicity as compared with GP. There is increasing interest in a biweekly split administration of DP to reduce its toxicity. Hypothesis was that first-line biweekly DP is as safe as GP in the elderly or poor performance status (PS) patients. METHODS: Chemotherapy-naïve patients with advanced NSCLC (IIIB/IV) who were elderly (65<) or PS (ECOG 2) were randomized to DP or GP arm by balancing for ECOG (0-1 vs...
March 24, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28326834/thoracic-radiation-therapy-could-give-survival-benefit-to-elderly-patients-with-extensive-stage-small-cell-lung-cancer
#10
Changchun An, Wang Jing, Yan Zhang, Sujing Liu, Haiyong Wang, Kunli Zhu, Li Kong, Hongbo Guo, Hui Zhu
AIM: To evaluate the effect of thoracic radiation therapy (TRT) in elderly patients (aged ≥65 years) with extensive-stage small-cell lung cancer (ES-SCLC). PATIENTS & METHODS: This study reviewed the records of 118 elderly patients with ES-SCLC (all with distant metastasis) through January 2006-December 2013. The patients were divided into either a chemotherapy (ChT)/TRT-combination group or a ChT-alone group. RESULTS: The median survival time and 3-year overall survival rates in the ChT/TRT group were significantly higher than those in the ChT-alone group (17...
February 24, 2017: Future Oncology
https://www.readbyqxmd.com/read/28296721/single-pemetrexed-is-noninferior-to-platinum-based-pemetrexed-doublet-as-first-line-treatment-on-elderly-chinese-patients-with-advanced-nonsquamous-nonsmall-cell-lung-cancer
#11
COMPARATIVE STUDY
Xiaolin Pu, Wei Li, Binbin Lu, Zhaoxia Wang, Min Yang, Weifei Fan, Lijuan Meng, Zhigang Lv, Yuchun Xie, Jun Wang
BACKGROUND: To evaluate the clinical efficacy and toxicity of single pemetrexed treatment compared with platinum-based pemetrexed doublet pemetrexed-based as first-line treatment for advanced nonsquamous nonsmall cell lung cancer (NS-NSCLC) in elderly Chinese patients. METHODS: The study retrospectively reviewed 175 elderly Chinese patients with NS-NSCLC from June 2010 to September 2013: 90 patients received single pemetrexed treatment, 45 received pemetrexed plus oxaliplatin, and 40 received pemetrexed plus carboplatin...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28276698/the-role-of-checkpoint-inhibitors-immunotherapy-in-advanced-non-small-cell-lung-cancer-in-the-elderly
#12
Assunta Sgambato, Francesca Casaluce, Cesare Gridelli
Immune checkpoint inhibition is a novel treatment modality that has brought a new hope to patients with advanced NSCLC. Several molecules targeting cytotoxic T-lymphocyte antigen 4 (CTLA4) or programmed cell death 1 receptor/programmed death ligand-1 (PD1/PD-L1) pathways are under evaluation in NSCLC and three of them are currently approved: nivolumab and atezolizumab for advanced NSCLC after prior chemotherapy and pembrolizumab for advanced NSCLC expressing PD-L1 ≥ 1% after at least one prior chemotherapy regimen and > 50% as a first-line response...
February 20, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28191295/small-cell-carcinoma-of-the-prostate-in-an-elderly-patient-a-case-report-and-review-of-the-literature
#13
Dale Alan Whitaker, Daniel H Miller, Niveditha Jagadesh, Gerald W Strong, Lauren Hintenlang, William B Schenk, Gregory A Broderick, Katherine S Tzou, Steven J Buskirk
Prostate cancer is the most common malignancy of men in the United States. Small-cell carcinoma (SCC), which typically presents as an aggressive lung malignancy, is a rare diagnosis within the setting of prostate cancer pathology. Due to its limited prevalence, little information regarding the treatment and prognosis of this disease in large populations is available. To date our current knowledge base is largely limited to case reports and retrospective case reviews. The mainstay of treatment for this particular histology most often involves a multimodality approach utilizing chemotherapy in conjunction with radiation therapy, androgen deprivation therapy, or prostatectomy...
November 17, 2016: Rare Tumors
https://www.readbyqxmd.com/read/28168322/radical-hypo-fractionated-radiotherapy-with-volumetric-modulated-arc-therapy-in-lung-cancer-a-retrospective-study-of-elderly-patients-with-stage%C3%A2-iii-disease
#14
D Franceschini, F De Rose, L Cozzi, P Navarria, E Clerici, C Franzese, T Comito, A Tozzi, C Iftode, G D'Agostino, M Sorsetti
BACKGROUND: This study aimed to analyse the feasibility and acute toxicity of radical hypo-fractionated radiotherapy (RT) for elderly patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We conducted a retrospective evaluation of treatment with volumetric modulated arc therapy (VMAT) of elderly patients affected by stage III inoperable NSCLC. The dose prescription was 56 Gy in 20 fractions, 55 Gy in 22 fractions, or 50 Gy in 20 fractions...
February 6, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28161553/lower-incidence-of-esophagitis-in-the-elderly-undergoing-definitive-radiation-therapy-for-lung-cancer
#15
Payal D Soni, Philip S Boonstra, Matthew J Schipper, Latifa Bazzi, Robert T Dess, Martha M Matuszak, Feng-Ming Kong, James A Hayman, Randall K Ten Haken, Theodore S Lawrence, Gregory P Kalemkerian, Shruti Jolly
INTRODUCTION: Most patients with lung cancer are elderly and poorly represented in randomized clinical trials. They are often undertreated because of concerns about their ability to tolerate aggressive treatment. We tested the hypothesis that elderly patients undergoing definitive lung radiation might tolerate treatment differently than younger patients. METHODS: A total of 125 patients who underwent definitive lung radiotherapy were identified from a prospective institutional database (University of Michigan cohort)...
March 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28156495/palliative-care-and-health-care-utilization-at-the-end-of-life
#16
Wendi G LeBrett, Rayna Matsuno, Lindsay Hwang, Isabel Boero, Eric Roeland, Heidi Yeung, James Don Murphy
152 Background: Palliative care's role in oncology has expanded, but its impact on aggressiveness of care at the end of life has not been characterized at the population level. METHODS: This matched retrospective cohort study examined the effect of an encounter with palliative care on healthcare utilization at the end of life among 6,580 Medicare beneficiaries with advanced prostate, breast, lung, or colorectal cancer. We compared healthcare utilization before and after palliative care consultation to a matched non-palliative care cohort...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156492/food-as-medicine-a-randomized-controlled-trial-rct-of-home-delivered-medically-tailored-meals-hdmtm-on-quality-of-life-qol-in-metastatic-lung-and-non-colorectal-gi-cancer-patients
#17
Raymond Mailhot Vega, Lisa Zullig, Alissa Wassung, Dorella Walters, Noah Berland, Kevin Lee Du, Jiyoung Ahn, Cynthia G Leichman, Deirdre Jill Cohen, Ping Gu, Abraham Chachoua, Lawrence P Leichman, Karen Pearl, Peter B Schiff
155 Background: Malnutrition incidence in cancer approaches 85%, disproportionately burdening those with lung, GI, and advanced stage cancers. Malnourished patients have impaired chemotherapy response, shorter survival, longer hospital stays, and decreased QoL. Home delivered meals are nutritional interventions that improve patient well-being, nutrition, and lower healthcare costs in the elderly but have not been studied as an intervention in cancer patients. HDMTM are nutritionist prescribed home delivered meals tailored to patient's symptoms, co-morbidities, and health needs...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28117221/comparative-effectiveness-and-resource-usage-in-patients-receiving-first-line-taxane-based-chemotherapy-for-stage-iv-non-small-cell-lung-cancer-in-a-us-community-oncology-setting
#18
Jared Weiss, Rex W Force, Brook A Pugmire, Teri Peterson, Claudio Faria, Sandra Margunato-Debay, Manish B Patel
BACKGROUND: Weekly (qw) nanoparticle albumin-bound (nab)-paclitaxel was approved for advanced non-small-cell lung cancer based on the results from a phase III trial in which nab-paclitaxel/carboplatin demonstrated a significantly greater response rate compared with paclitaxel/carboplatin every 3 weeks (q3w). Little information exists on relative real-world results. MATERIALS AND METHODS: The present retrospective study used data from a national electronic medical record database...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27920688/complete-and-sustained-response-with-a-doublet-chemotherapy-protocol-in-an-81-year-old-patient-with-metastatic-breast-cancer
#19
Taynah Cascaes Puty, Gabriel S A Brito, Mariana S Dias, Henrique C Miranda, Juliana R Chaves, Heryvelton L Freitas, Luís E W Carvalho
Metastatic breast cancer (MBC) entails an overall 5-year survival of approximately 25%. The choice of therapy is influenced by expression of the HER2 gene and hormone receptors, by a disease-free interval, and by age. The use of paclitaxel combined with gemcitabine (doublet protocol) has shown efficacy as first-line treatment for MBC in either initial or maintenance therapy when compared to monotherapy with paclitaxel. There is evidence showing that the doublet protocol is a good alternative to maintenance therapy in women under 50 years old...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27901246/chemotherapy-for-advanced-non-small-cell-lung-cancer-in-the-elderly-population
#20
Fábio Nasser Santos, Tiago Biachi de Castria, Marcelo Rocha Souza Cruz, Rachel Riera
BACKGROUND: Approximately 50% of patients with newly diagnosed non-small cell lung cancer (NSCLC) are over 70 years of age at diagnosis. Despite this fact, these patients are underrepresented in randomized controlled trials (RCTs). As a consequence, the most appropriate regimens for these patients are controversial, and the role of single-agent or combination therapy is unclear. In this setting, a critical systematic review of RCTs in this group of patients is warranted. OBJECTIVES: To assess the effectiveness and safety of different cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIB and IV) NSCLC...
September 2016: São Paulo Medical Journal, Revista Paulista de Medicina
keyword
keyword
109146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"